Search

Within process development, numerous experimental studies are undertaken to establish, optimize and characterize individual bioprocess unit operations. These studies pursue diverse objectives such as enhancing titer or minimizing impurities. Consequently, Design of Experiment (DoE) studies are planned and analyzed independently from each other, making it challenging to interlink individual data sets to form a comprehensive overview at the conclusion of the development process. This paper elucidates the methodology for constructing a Life-Cycle-DoE (LDoE), which integrates data-driven process knowledge through design augmentations. It delves into the strategy, highlights the challenges encountered and provides solutions for overcoming them. The LDoE approach facilitates the augmentation of an existing model with new experiments in a unified design. It allows for flexible design adaptations as per the requirements of subject matter experts (SME) during process development, concurrently enhancing model predictions by utilizing all available data. The LDoE boasts a broad application spectrum as it consolidates all data generated within bioprocess development into a single file and model. The study demonstrates that the LDoE approach enables a process characterization study (PCS) to be performed solely with development data. Furthermore, it identifies potentially critical process parameters (pCPPs) early, allowing for timely adaptations in process development to address these challenges.

Maximizing the value of each available data point in bioprocess development is essential in order to reduce the time-to-market, lower the number of expensive wet-lab experiments, and maximize process understanding. Advanced in silico methods are increasingly being investigated to accomplish these goals. Within this contribution, we propose a novel integrated process model procedure to maximize the use of development data to optimize the Stage 1 process validation work flow. We generate an integrated process model based on available data and apply two innovative Monte Carlo simulation-based parameter sensitivity analysis linearization techniques to automate two quality by design activities: determining risk assessment severity rankings and establishing preliminary control strategies for critical process parameters. These procedures are assessed in a case study for proof of concept on a candidate monoclonal antibody bioprocess after process development, but prior to process characterization. The evaluation was successful in returning results that were used to support Stage I process validation milestones and demonstrated the potential to reduce the investigated parameters by up to 24% in process characterization, while simultaneously setting up a strategy for iterative updates of risk assessments and process controls throughout the process life-cycle to ensure a robust and efficient drug supply.